Moderna 11 may 2026 Hantavirus cases spark brief surge in pharma and biotech stocks — here’s why trading is so volatile - CNBC
Moderna 11 may 2026 Moderna shares spike after pre-outbreak hantavirus vaccine work revealed - medwatch.com
Moderna 8 may 2026 Moderna Works on Hantavirus: Reports Claim the Biotech Giant Has Started Early-Stage Research of the Jab - International Business Times UK
Moderna 7 may 2026 Moderna’s mRNA flu vaccine more effective than current SOC - Clinical Trials Arena
Moderna 7 may 2026 Korea University and Moderna have been working on mRNA hantavirus vaccine since 2023 - Brussels Signal
Moderna 7 may 2026 Phase 3 trial finds Moderna mRNA flu vaccine outperforms standard vaccine in older adults - CIDRAP
Moderna 5 may 2026 Boston biotech firms back new effort to preserve U.S. edge in life sciences - The Business Journals
Moderna 4 may 2026 Vertex drops Moderna-partnered inhaled cystic fibrosis candidate after unresolved tolerability issues - Fierce Biotech
Moderna 4 may 2026 Biopharma bites: Tolerability sinks Vertex-Moderna's CF candidate, Takeda's immune win, and more from Amgen, Latus - FirstWord Pharma
Moderna 30 abr 2026 Moderna loses key mRNA patent in European vaccine fight - Life Sciences Intellectual Property Review
Moderna 28 abr 2026 Moderna Deploys Salesforce Agentforce Life Sciences to Unify Global Commercial Operations - HIT Consultant
Moderna 28 abr 2026 CureVac targets Moderna with 10-patent suit over Spikevax - Life Sciences Intellectual Property Review
Moderna 22 abr 2026 Moderna, after losing US funding, rebounds to start mRNA bird flu vaccine trial - BioPharma Dive
Moderna 22 abr 2026 Moderna launches mRNA bird flu vaccine trial after HHS cancels funding - The Washington Post